Protein conjugation with amphiphilic block copolymers for enhanced cellular delivery. (scientific article published on 16 April 2008)

Temperature-dependent aggregation and disaggregation of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer in aqueous solution

Q31134930

Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.

Q33982544

Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers

Q34669073

Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery

Q37263021

Pharmacokinetics and biodistribution of genetically-engineered antibodies

Q38328336

Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides.

Q38331375

The interaction of particulate horseradish peroxidase (HRP)-anti HRP immune complexes with mouse peritoneal macrophages in vitro

Q41158462

Fatty acid acylated peroxidase as a model for the study of interactions of hydrophobically-modified proteins with mammalian cells.

Q41298218

Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells

Q44285589

Adsorptive endocytosis and membrane recycling by cultured primary bovine brain microvessel endothelial cell monolayers

Q48905056

A new procedure for the synthesis of polyethylene glycol-protein adducts; Effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and α2-macroglobulin

Q72711204

P433

issue

P304

page(s)

1071-1077

P577

publication date

2008-04-16

P1433

published in

Bioconjugate Chemistry

Q2343023

P1476

title

Protein conjugation with amphiphilic block copolymers for enhanced cellular delivery

P478

volume

Reverse relations

cites work (P2860)

Q34079647	Agile delivery of protein therapeutics to CNS
Q27016563	Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases
Q30354932	Brain delivery of proteins via their fatty acid and block copolymer modifications
Q36423113	Chylomicron formation and secretion is required for lipid-stimulated release of incretins GLP-1 and GIP.
Q30535357	Conjugates of superoxide dismutase 1 with amphiphilic poly(2-oxazoline) block copolymers for enhanced brain delivery: synthesis, characterization and evaluation in vitro and in vivo
Q48489678	Drug transport into the central nervous system: using newer findings about the blood-brain barriers
Q39382065	Formulation and characterization of poloxamine-based hydrogels as tissue sealants
Q54380286	Influence of Pluronic® F68 on Ceftazidime Biological Activity in Parenteral Solutions
Q47933830	Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity
Q30592302	Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity
Q39567567	Pluronic-based cationic block copolymer for forming pDNA polyplexes with enhanced cellular uptake and improved transfection efficiency
Q34390003	Pluronic-modified superoxide dismutase 1 attenuates angiotensin II-induced increase in intracellular superoxide in neurons
Q36716915	Poly(2-oxazoline)s as polymer therapeutics
Q38787540	Poly(ester amine) constructed from polyethylenimine and pluronic for gene delivery in vitro and in vivo.
Q37888857	Principles of strategic drug delivery to the brain (SDDB): development of anorectic and orexigenic analogs of leptin.
Q34761834	Protein modification with amphiphilic block copoly(2-oxazoline)s as a new platform for enhanced cellular delivery
Q30499330	The utilization of pathogen-like cellular trafficking by single chain block copolymer
Q33755265	Transport across the blood-brain barrier of pluronic leptin.